Curcumin is one of the best-known ingredients in Japanese functional foods, sold for decades as “ukon” (turmeric) drinks and capsules. Brands abroad ask for it because it is familiar worldwide, but curcumin has a formulation problem that shapes almost every decision that follows: taken as plain turmeric extract, very little of it reaches the bloodstream.
This guide is for brand owners planning a curcumin product made in Japan. It covers why bioavailability-enhanced forms exist, what the human trials on absorption and joint comfort show, a liver-safety signal you should know about before you brief a factory, and how the ingredient is formulated.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a curcumin product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Plain curcumin is absorbed poorly; several enhancement technologies raise blood levels substantially, and a meta-analysis of joint-comfort trials found a modest benefit rated as low-quality evidence.
| Study | Design/What was analysed | Reported result |
|---|---|---|
| Randomised, open-label, crossover PK study, International Journal of Clinical Pharmacology and Therapeutics 2021 (PMID 34423771, PMC9097512) | 24 healthy men; single 90 mg dose of a colloidal (submicron) curcumin dispersion versus unformulated curcumin powder; sponsored by a Korean pharmaceutical company | Colloidal form reached 18.4–20.5× higher peak plasma level and 35.9–42.6× higher total absorption (AUC) than plain curcumin powder |
| Randomised, double-blind, crossover trial, J Nat Prod 2011;74(4):664–9 (PMID 21413691) | Human comparison of a standardised curcuminoid mixture versus its phospholipid (“phytosome”) formulation | Total curcuminoid absorption ~29-fold higher with the phytosome form; even so, the major compound detected was a metabolite, and plasma levels stayed below concentrations shown to be active in many laboratory assays |
| Randomised, double-blind, crossover trial, Mol Nutr Food Res 2021 (PMID 34665507) | 12 healthy adults; single 207 mg dose of curcumin, comparing native curcumin with seven formulations: liposomal, with turmeric oils, with adjuvants including piperine, submicron particles, phytosomal, a γ-cyclodextrin complex and micellar | Versus native curcumin, AUC rose significantly only with the micellar form (57-fold) and the γ-cyclodextrin complex (30-fold); the other five formulations, including the piperine-containing one, showed no significant increase |
| Systematic review and meta-analysis, BMC Complement Med Ther 2022;22:276 (PMID 36261810) | 15 randomised controlled trials, 1,670 people with knee osteoarthritis; curcuminoids alone versus placebo or an anti-inflammatory drug | Pain (VAS) and WOMAC scores improved versus placebo; results were not statistically different from the anti-inflammatory drug comparator; authors rated the evidence low-quality and called for caution |
Four points worth weighing:
- “Enhanced” is not one technology. Piperine (black pepper extract), phospholipid complexes, micronisation, nanoparticle and solid-lipid-particle systems all claim to improve absorption, but they are not interchangeable, and results differ by method and by study.
- Piperine’s own evidence is weaker than its reputation. An independent crossover pharmacokinetic reappraisal (PMC12144411) found piperine added little to no meaningful benefit to free curcumin levels, even at high doses, a finding echoed by a separate USP safety review (see below). The often-quoted “2000% increase” comes from a single 1998 study and has not held up consistently in later, independently run comparisons.
- The osteoarthritis trials were in a diagnosed patient population, and the meta-analysis authors themselves flagged low study quality and heterogeneity. That evidence describes what was studied in people with a disease — it is not a basis for a product to claim it treats, prevents or manages any joint condition.
- Funding and design. The colloidal-curcumin PK study above was sponsored by a Korean pharmaceutical company that employed one of the authors; it was open-label and enrolled only men. Read the funding line and the design of any absorption study you plan to cite.
Checked against the published abstracts on 13 October 2026.
An honest safety note: rare but documented liver injury
Turmeric and curcumin supplements have been linked to rare cases of liver injury in multiple countries, and this deserves a straightforward mention rather than a footnote.
- A 2026 comprehensive review by the US Pharmacopeia (Pharmaceutical Biology 64(1):866–901, PMID 42364655) covering international spontaneous-reporting data reports that Health Canada identified 12 Canadian cases, all with confounding factors, and also reviewed over 60 international cases, including 3 deaths. It describes onset typically 1–4 months after starting use, injury that generally resolves on stopping the product, and rare cases of acute liver failure. The authors describe the likely mechanism as idiosyncratic and immune-mediated, with emerging evidence of genetic susceptibility.
- A case series from the US Drug-Induced Liver Injury Network (American Journal of Medicine, 2023, PMID 36252717) reviewed adjudicated cases enrolled between 2004 and 2022 and found 10 turmeric-associated liver injury cases, all enrolled since 2011 (8 of 10 in women, median age 56). Five patients were hospitalised and one died of acute liver failure. Seven of the 10 carried the HLA-B*35:01 gene variant (two homozygous), far above its frequency in the general population — a genetic-susceptibility signal consistent with the USP review. Three of the seven implicated products chemically confirmed to contain turmeric also contained piperine.
- An analysis of Italy’s Phytovigilance database for the Tuscany region, with a systematic review of case reports (British Journal of Clinical Pharmacology, 2021, PMID 32656820), documented seven cases of acute hepatitis linked to turmeric up to September 2019, associated with high-bioavailability, high-dose curcumin/curcuminoid formulations.
- Italy’s Ministry of Health made liver- and biliary-related label warnings mandatory in 2019 for food supplements containing Curcuma preparations, with advice to consult a doctor when taking medicines, and strengthened those warnings in 2022, as summarised in the USP review above.
None of this means curcumin is unsafe for the vast majority of users, and clinical trials of curcumin generally have not reported organ toxicity. But the signal is real, documented in peer-reviewed case series, and tied in part to the very high-absorption formulations this market favours and to piperine-combined products specifically. A responsible brand discloses this rather than treating “clinically studied” absorption claims as a pure selling point, and should not make any liver-related function claim for a curcumin product given this evidence.
What Japanese products say
Japan’s Foods with Function Claims system has accepted curcumin notifications for maintaining memory and attention that decline with age — squarely within the “healthy ageing” framing, not a joint or liver claim.
Notified examples describe helping to maintain memory, or memory and attention, that tend to decline with age — at daily curcumin amounts that differ between products. The wording describes everyday cognitive functions of healthy older adults, not a medical condition.
Two lessons for a brand abroad:
- The notified function is about memory and attention, not joints or liver. If your interest in curcumin was for joint comfort, know that this is not the function Japan has accepted evidence for under this system; the joint evidence sits in the independent trials discussed above, with lower certainty.
- A Japanese notification is a Japanese mechanism for Japanese labels. It does not transfer to your market. Your own regulator’s rules govern any function wording you use abroad.
💬 Need an evidence summary for your regulatory adviser that separates the bioavailability data from the Japanese notifications? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe curcumin by what was studied, in which form and at what dose — and disclose the liver-safety signal rather than making a liver claim.
| Safer wording | Wording to avoid |
|---|---|
| ”Contains [X] mg curcumin from [named form]” with the absorption data for that specific form | ”2000% more bioavailable” without naming the study and its limits |
| ”Studied in relation to joint comfort” (where a specific trial is named) | “Treats arthritis”, “anti-inflammatory” framed as a medical function, or any joint-disease name |
| No liver-function claim at all | ”Supports liver health/detox” or any hepatic-function wording |
| ”Curcumin is studied for memory maintenance with age” only where your market’s rules allow a cognitive claim | Copying Japan’s exact notified wording into a market that has not accepted that evidence |
How curcumin is formulated
Because plain curcumin absorbs so poorly, the choice of technology is the first specification decision, not an afterthought.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Hard capsule or softgel with an enhanced-absorption curcumin (colloidal, micellar, phytosome, cyclodextrin complex, micronised or nanoparticle) | Matches the form used in most absorption studies; smaller effective dose | Cost per unit is higher than plain extract; each technology has different, non-interchangeable evidence |
| Powder stick or drink with standardised turmeric/curcuminoid extract | Familiar Japanese “ukon drink” format; combines easily with other botanicals | Plain extract has the weakest absorption; consider whether an enhanced form suits the format |
| Softgel with an oil-based curcumin dispersion | Pairs with other lipid-soluble actives | Stability of the oil base |
Decisions that shape the specification:
- Enhancement technology, named specifically. “Bioavailability-enhanced” is not a specification. Ask the supplier which technology is used (colloidal dispersion, phospholipid/phytosome complex, micellar solubilisation, cyclodextrin complex, micronisation, solid-lipid particle) and for the pharmacokinetic data behind that exact material, since the fold-increases above are not interchangeable between technologies.
- Whether piperine is included, and why. Piperine is common in commercial blends, but independent testing found it added little measurable benefit to free curcumin levels, and it appeared in a meaningful share of the documented liver-injury cases (including alongside turmeric itself). Piperine also affects how the body processes other compounds via the liver, which matters for anyone taking medication. Weigh this specifically before including it.
- Amount per serving. Match the amount, and the specific technology, to any study you intend to cite — the single doses in the absorption studies above ranged from 90 mg to 207 mg depending on the form and study.
- Packaging and stability. Curcumin degrades with light and oxidation; opaque packaging and antioxidant-compatible formulation matter.
- Your market’s status for curcumin/turmeric. Some regulators (Italy, and Health Canada’s 2025 labelling call, among others) have moved to require liver-related warning labels on curcumin/turmeric supplements specifically. Confirm your own market’s current labelling requirements before you commit to a formula and artwork.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Curcumin itself has long been used in Japanese foods and drinks and is accepted under the Foods with Function Claims system, so it clears this check on its own. The companion ingredients in a “joint” or “healthy ageing” formula are where problems arise — some botanicals sold freely elsewhere are treated as medicines in Japan and would stop the whole product being made as a food. See the Japan-made supplement OEM page, and compare with our collagen peptide and astaxanthin guides if you are building a combined joint or healthy-ageing product.
Before you ask for a quotation
A factory can quote accurately once the technology, the amount, the companions and the packaging are fixed.
- Curcumin source and enhancement technology, named specifically, with its own pharmacokinetic data
- Whether piperine is included, and the reasoning
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Packaging
- Countries you will sell in, and their current labelling rules for turmeric/curcumin
💬 Ready to design a Japan-made curcumin product? Send us the concept — technology, amount, form and the countries you will sell in.
Frequently asked questions
1. Does curcumin absorb well on its own?
No. Plain curcumin has very poor natural oral bioavailability, which is why the market has moved to enhanced forms such as colloidal dispersions, phospholipid complexes, micellar systems and cyclodextrin complexes — each with its own, non-interchangeable absorption data.
2. Which enhanced form has the strongest evidence?
It varies by study. A head-to-head crossover trial of seven formulations found significant increases only with a micellar form (57-fold) and a γ-cyclodextrin complex (30-fold); the other five, including a piperine-containing one, showed no significant increase. A separate, company-sponsored study in 24 men found a colloidal formulation raised absorption 18–21× (peak level) and 36–43× (total absorption) over plain curcumin powder.
3. Does curcumin help with joint comfort?
A 2022 meta-analysis of 15 trials in people with knee osteoarthritis found improved pain and function scores versus placebo, similar to an anti-inflammatory drug comparator, but the authors rated the evidence low-quality with substantial heterogeneity. This is research in a diagnosed population, not a basis for a product joint-health claim.
4. Is curcumin safe for the liver?
For most users, yes, and clinical trials generally have not reported liver toxicity. But peer-reviewed case series from the US and Italy document rare, sometimes serious liver injury linked to turmeric/curcumin supplements, often with high-absorption formulations or piperine-containing products, and a likely genetic-susceptibility component. We do not recommend any liver-function claim for a curcumin product, and your labelling should reflect current regulatory guidance in your market.
5. Is curcumin recognised in Japan’s Foods with Function Claims system?
Yes, for maintaining memory and attention that decline with age — not for joints or liver function. The daily curcumin amount differs between notified products, so match the amount to the evidence behind the specific notification.
Sources: Comparative pharmacokinetics study of a highly bioavailable curcumin formulation in healthy adult subjects, International Journal of Clinical Pharmacology and Therapeutics 2021;59(10):684–690 (PMID 34423771, PMC9097512); “Comparative Absorption of a Standardized Curcuminoid Mixture and Its Lecithin Formulation”, Journal of Natural Products 2011;74(4):664–9 (PMID 21413691); “Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability”, Molecular Nutrition & Food Research 2021;65(24):e2100613 (PMID 34665507); “A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability” (PMC12144411); “Efficacy and safety of curcuminoids alone in alleviating pain and dysfunction for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials”, BMC Complementary Medicine and Therapies 2022;22:276 (PMID 36261810); “Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP”, Pharmaceutical Biology 2026;64(1):866–901 (PMID 42364655); “Liver Injury Associated with Turmeric—A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]”, American Journal of Medicine 2023;136(2):200–206 (PMID 36252717); “Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports”, British Journal of Clinical Pharmacology 2021 (PMID 32656820); Consumer Affairs Agency, Foods with Function Claims system. Checked on 13 October 2026.